ARTA treatment of metastatic castration‑resistant prostate cancer – case report


MUDr. Igor Richter, Ph.D.1,2,3; doc. MUDr. Josef Dvořák, Ph.D.2; MUDr. Vladimír Šámal, Ph.D.4; MUDr. Jiří Bartoš, MBA1

1 Onkologické oddělení, Krajská nemocnice Liberec

2 Onkologická klinika 1. LF UK a Fakultní Thomayerovy nemocnice, Praha

3 Fakulta zdravotnických studií, Technická univerzita Liberec

4 Urologické oddělení, Krajská nemocnice Liberec



The treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) has rapidly evolved over the past 10 years. The addition chemotherapy (docetaxel, cabazitaxel), androgen receptor targeted agents (ARTA - abiraterone, enzalutamide) and radium 223 has improved outcomes for patients with mCRPC. Abiraterone in our clinical practice is applied most often before the docetaxel-based chemotherapy. We present a case study of patient with mCRPC treated by abirateron (before chemotherapy) for four years.


Key words

prostate cancer, metastases, abiraterone, toxicity



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...